Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04531670 · ClinicalTrials.gov registry record · NA

Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program

A NA study of Opioid Use Disorder and HIV Prevention Program, sponsored by University of Connecticut.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT04531670 is a NA study of Opioid Use Disorder and HIV Prevention Program that has completed, run by University of Connecticut. The registered enrollment target is 50 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04531670, a NA study of Opioid Use Disorder and HIV Prevention Program, has completed, sponsored by University of Connecticut.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This is a pilot study of an integrated rapid access HIV prevention program for People who inject drugs (PWID) called iRaPID. The program incorporates same-day access to Pre-exposure Prophylaxis (PrEP) and Opioid Agonist Therapy (OAT).

Interventions

  • OTHER Standard of Care
  • BEHAVIORAL iRaPID

Study Locations (1)

Connecticut

  • Yale Clinical and Community Research - New Haven

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2021-07-26
Est. Completion 2023-02-28
Phase NA

Sponsor

University of Connecticut

107 total trials

What the Registry Record Tells You About NCT04531670

The ClinicalTrials.gov registry entry for NCT04531670 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The listed sponsor is University of Connecticut, which has 107 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT04531670 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT04531670 about?

NCT04531670 is a clinical study titled "Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program". This is a pilot study of an integrated rapid access HIV prevention program for People who inject drugs (PWID) called iRaPID. The program incorporates same-day access to Pre-exposure Prophylaxis (PrEP) and Opioid Agonist Therapy (OAT).

What is the current status of trial NCT04531670?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2021-07-26. Estimated completion is 2023-02-28.

What conditions does trial NCT04531670 study?

This clinical trial studies the following conditions: Opioid Use Disorder, HIV Prevention Program.

What interventions are being tested in trial NCT04531670?

The interventions under investigation include: Standard of Care (OTHER), iRaPID (BEHAVIORAL).

Who is sponsoring clinical trial NCT04531670?

This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04531670 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.